In pediatrics, a key milestone is a phase I clinical trial of a TLR9 agonist (GNKG168) in children with acute lymphoblastic leukemia (ALL) with minimal residual disease [216]. The gene discussed is TLR9; the disease is acute lymphoblastic leukemia.